A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Alkermes plc (NASDAQ:ALKS) on Monday released topline results from the randomized double-blind treatment period of the ...

Alkermes ALKS announced positive top-line data from the phase II Vibrance-1 study, which evaluated its novel, investigational ...

Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial.

Ireland-based Alkermes has announced positive topline results from the randomized double-blind treatment period of the ...

Topline data were announced from two phase 3 trials evaluating oveporexton in patients with narcolepsy type 1.

Takeda is on track to submit its much-hyped narcolepsy drug to regulators this fiscal year after the orexin receptor 2 (OX2R) ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts have guessed it could ultimately generate billions in sales.

Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.

Second Quarter Revenues of $390.7 Million - - GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 - - Company Reiterates 2025 Financial Expectations ...

Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with ...